Venturepharm Laboratories Limited

Venturepharm is the largest global provider of pharmaceutical development service in China. Venturepharm provides full service of drug discovery and development that take new drugs from "Idea to patients." These include API (Active Pharmaceutical Ingredient), formulation development, clinical trial, product registration, marketing & sales to pharmaceutical distributors and patients in China and overseas. Listed as a Hong Kong public company (8225), Venturepharm (China) has experienced dramatic success since its inception in 1999. Powered with 7 of VSmart? technology platforms, it has over 400 non-patent infringed products approved, or pending. In addition, 6 of NCEs (new chemical entities) are at preclinical stage. These products encompass over 13 major therapeutic areas. In 2004, Venturepharm was valued by FORTUNE magazine as one of the five most promising companies in China. Since 2000, Venturepharm has achieved revenue CAGR of 133% and EPS CAGR of 383% annually.